CoChat

An Asian Multicenter Clinical Trial to Assess the Efficacy and Tolerability of Acarbose Compared With Placebo in Type 2 Diabetic Patients Previously Treated With Diet

Chan, Juliana CN, Chan, Kin-Wei A, HO, Larry LT, Fuh, Martin MC, Horn, Lee Chung, Sheaves, Richard, Panelo, Araceli A, Kim, Duk-Kyu, Embong, Mustaffa, For the Asian Acarbose Study Group · 1998 · Diabetes Care
Cited by 58

The DOI matches its Crossref record.

Abstract

OBJECTIVE: To assess the efficacy, safety, and tolerability of acarbose versus placebo during a 24-week treatment period in Asian type 2 diabetic patients with dietary failure. RESEARCH DESIGN AND METHODS: After a 6-week screening period, 126 multiethnic Asian type 2 diabetic patients (64 men, 62 women; mean age ± SD, 53.4 ± 10 years) were randomized to receive acarbose (n = 63) or placebo (n = 63). The dosage was increased from 50 mg t.i.d. at week 0 to 100 mg t.i.d. at week 4. Patients were then followed up at weeks 10, 16, and 24. At each visit, body weight, blood pressure, and metabolic indexes were measured. At weeks 0 and 24, fasting plasma glucose and insulin were measured before and 1 h after the administration of an individually tailored breakfast. RESULTS: Using the intention-to-treat analysis, there were greater reductions in (mean [95% CI]) HbA1c (−0.70 [−1.00 to −0.39] vs. −0.27% [−0.54 to 0]; P = 0.04), fasting plasma glucose (−0.37 [−0.75 to 0.02] vs. 0.41 mmol/1 [−0.08 to 0.90]; P = 0.017) and 1-h plasma glucose (−0.77 [−1.44 to −0.10] vs. 0.65 mmol/1 [−0.07 to 1.36]; P = 0.05) in the acarbose group compared with the placebo group. With acarbose treatment, 78% of patients achieved an HbA1c <8% compared with 56% in the placebo group (P = 0.003). There was a greater reduction in body weight (−1.31 [−2.46 to −0.15] vs. 0.16 kg [−3.36 to 0.10]; P = 0.02) and higher incidence of flatulence (56 vs. 37%; P = 0.032) in the acarbose than in the placebo group. Using baseline HbA1c and race as covariates, there were no significant interethnic differences in treatment responses (P = 0.232 for treatment-race interaction; P < 0.001 for treatment effect). The dropout rates were similar between the two groups (acarbose, 11 of 63; placebo, 6 of 63). There were no significant laboratory adverse events in either group. CONCLUSIONS: In this multicenter study involving six ethnic groups, acarbose 100 mg t.i.d. was an effective, safe, and generally well-tolerated therapy in Asian type 2 diabetic patients with dietary failure. In some patients with troublesome gastrointestinal symptoms, a lower dosage may be necessary.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.2337/diacare.21.7.1058

Cites

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cited by

See all 58

Metadata

Authors
Chan, J. C., Chan, K.-W. A., HO, L. L., Fuh, M. M., Horn, L. C., Sheaves, R., Panelo, A. A., Kim, D.-K., Embong, M., & For the Asian Acarbose Study Group
Venue
Diabetes Care
Published
1998-07-01
Volume
21
Issue
7
Pages
1058-1061
ISSN
  • 0149-5992 (ISSN-L)
  • 1935-5548
OpenAlex
W2023432450
Cited by
58
References
0
FWCI
1.63
Type
journal article
Language
en
Open access
closed

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: An Asian Multicenter Clinical Trial to Assess the Efficacy and Tolerability of Acarbose Compared With Placebo in Type 2 Diabetic Patients Previously Treated With Diet. https://app.cochat.ai/papers/10.2337/diacare.21.7.1058
The paper
Chan, J. C., Chan, K.-W. A., HO, L. L., Fuh, M. M., Horn, L. C., Sheaves, R., Panelo, A. A., Kim, D.-K., Embong, M., & For the Asian Acarbose Study Group. (1998). An Asian Multicenter Clinical Trial to Assess the Efficacy and Tolerability of Acarbose Compared With Placebo in Type 2 Diabetic Patients Previously Treated With Diet. Diabetes Care. https://doi.org/10.2337/diacare.21.7.1058

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.